

IFW

PATENT

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450 on the date set forth below.

Ginger M. Graff

Date

8/18/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/790,417
Filed: March 1, 2004
Applicant: Charles A. Mesko
Title: COMPOSITION FOR INCREASING LEVELS OF HORMONES AND A
METHOD FOR PREPARATION OF SAID COMPOSITION
Examiner: Unknown
Art Unit: 1614
Conf. No.: 1471
Atty. Docket: MESK-30

Cincinnati, Ohio

August 18, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. §§§ 1.56, 1.97 and 1.704, the references listed on the attached supplemental Form PTO-1449 are called to the attention of the United States Patent and Trademark Office in connection with the above-identified patent application. Copies of the cited references are attached hereto.

The Examiner is respectfully requested to review each reference cited and to note the review on the attached PTO-1449 form and to reach his or her own independent determination of its materiality, if any.

A copy of the International Search Report in the counterpart PCT patent application is enclosed. This Search Report was received on July 18, 2005.

Certification under 37 C.F.R. § 1.97(e)(1)

Each item of information contained in the Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Certification under 37 C.F.R. § 1.704(d)


The foreign patent office communication cited herein was not received by any individual designated in 1.56(c) more than thirty days prior to submission of this Supplemental Information Disclosure Statement.

Conclusion

No fee is due for this submission in accordance with C.F.R. 37, §§ 1.97(e)(2) and 1.704(d). However, should any fees be deemed required, the Commissioner is hereby authorized to charge any such fees to Deposit Account No. 23-3000.

Respectfully submitted,

WOOD, HERRON & EVANS, L.L.P.

By: 
David E. Jefferies, Reg. No. 46,800

Wood, Herron & Evans, L.L.P.
2700 Carew Tower
Cincinnati, Ohio 45202
(513) 241-2324 (voice)
(513) 421-7269 (facsimile)

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. MESK/30		SERIAL NO. 10/790,417							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Charles A. Mesko									
(37 CFR 1.98(b))				FILING DATE March 1, 2004		GROUP 1614							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		PATENT NUMBER						ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	A.A	6	3	9	9	5	7	9	06/04/02	Lenoble et al.			08/15/00
	A.B												
	A.C												
	A.D												
	A.E												
	A.F												
	A.G												
	A.H												
	A.I												
	A.J												
	A.K												
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS													
		DOCUMENT NUMBER		PUBLICATION DATE		COUNTRY OR PATENT OFFICE			CLASS	SUBCLASS	TRANSLATION (YES/NO)		
	A.L												
	A.M												
	A.N												
	A.O												
	A.P												
	A.Q												
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)													
	A.R	International Search Report, mailed July 15, 2005 and received July 18, 2005.											
	A.S	U.S. Patent Application Publication No. 2003/0211185, Alexis, pub. Nov. 13, 2003.											
	A.T	R. Chaterjee et al., <u>Post-transplant complications. Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies</u> , Bone Marrow Transplantation, vol. 29, no. 7, Apr. 1, 2002, pp. 607-610.											
EXAMINER									DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.													

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. MESK/30		SERIAL NO. 10/790,417	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b)) (Use several sheets if necessary)				APPLICANT Charles A. Mesko			
				FILING DATE March 1, 2004		GROUP 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
	B.R	D.G. Dmitriev et al., <u>A new approach to raising efficiency of pharmacotherapy of erectile dysfunction</u> , Database Biosis (online), Biosciences Information Service, Philadelphia, PA, 2002, 1 page.					
	B.S	Wang et al., <u>Morinda citrifolia (Noni): A literature review and recent advances in Noni research</u> , Acta Pharmacologica Sinica, China, vol. 23, no. 12, Dec. 23, 2002, pp. 1127-1141.					
	B.T	J. Chen et al., <u>Effect of the Plant-Extract Osthole on the Relaxation of Rabbit Corpus Cavernosum Tissue In Vitro</u> , Journal of Urology, vol. 163, no. 6, June, 2000, pp. 1975-1980.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							